As of 2025-09-18, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,203.23 mil USD. TXG's TTM EBITDA according to its financial statements is -101.17 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 15.2x | 13.8x |
| Forward P/E multiples | 14.6x - 18.5x | 16.8x |
| Fair Price | (8.70) - (9.17) | (9.24) |
| Upside | -167.7% - -171.3% | -171.8% |
| Date | EV/EBITDA |
| 2025-09-16 | -12.30 |
| 2025-09-15 | -12.50 |
| 2025-09-12 | -11.62 |
| 2025-09-11 | -12.14 |
| 2025-09-10 | -11.56 |
| 2025-09-09 | -12.68 |
| 2025-09-08 | -13.21 |
| 2025-09-05 | -13.25 |
| 2025-09-04 | -12.77 |
| 2025-09-03 | -12.48 |
| 2025-09-02 | -12.52 |
| 2025-08-29 | -13.31 |
| 2025-08-28 | -13.64 |
| 2025-08-27 | -13.32 |
| 2025-08-26 | -13.33 |
| 2025-08-25 | -13.38 |
| 2025-08-22 | -13.67 |
| 2025-08-21 | -12.19 |
| 2025-08-20 | -12.51 |
| 2025-08-19 | -12.57 |
| 2025-08-18 | -12.63 |
| 2025-08-15 | -12.51 |
| 2025-08-14 | -12.36 |
| 2025-08-13 | -12.77 |
| 2025-08-12 | -11.83 |
| 2025-08-11 | -11.22 |
| 2025-08-08 | -11.19 |
| 2025-08-07 | -11.82 |
| 2025-08-06 | -11.65 |
| 2025-08-05 | -12.45 |
| 2025-08-04 | -12.90 |
| 2025-08-01 | -12.16 |
| 2025-07-31 | -12.62 |
| 2025-07-30 | -13.19 |
| 2025-07-29 | -13.30 |
| 2025-07-28 | -14.08 |
| 2025-07-25 | -13.43 |
| 2025-07-24 | -12.96 |
| 2025-07-23 | -12.83 |
| 2025-07-22 | -12.05 |
| 2025-07-21 | -10.27 |
| 2025-07-18 | -11.02 |
| 2025-07-17 | -11.39 |
| 2025-07-16 | -11.29 |
| 2025-07-15 | -11.11 |
| 2025-07-14 | -11.41 |
| 2025-07-11 | -11.82 |
| 2025-07-10 | -11.60 |
| 2025-07-09 | -10.96 |
| 2025-07-08 | -11.14 |